



STRATEGIC PARTNERSHIPS

EVEXIAS HEALTH SOLUTIONS

Discover a 503B pharmaceutical outsourcing facility dedicated to achievement of the highest standards in the industry.

# PRECISION PHARMACEUTICAL MANUFACTURING

## QUALITY

FarmaKeio Outsourcing employs rigorous validation processes to ensure that every single product achieves consistent potency and purity to help your patients reach optimal outcomes with every treatment.

## TRUST

FarmaKeio Outsourcing adheres to intense standards designated and enforced by current Good Manufacturing Practices, the same regulations managing leading patented pharmaceutical makers in the U.S.

## EFFICACY

Through innovative research and technology, FarmaKeio Outsourcing is foraging a new path in integrative medicine. Released in May 2023, FarmaKeio is the only 503B FDA registered facility to develop a patented pellet formulated with triamcinolone.

**SCAN NOW TO REGISTER WITH FARMAKEIO OUTSOURCING**



## FOR IMMEDIATE RELEASE

### MEDIA INQUIRIES

FarmaKeio Pharmacy Network

Danielle Tworek

media@farmakeio.com

817.725.9677



## FARMAKEIO OUTSOURCING® ANNOUNCES PATENTED FORMULATION OF REVOLUTIONARY HORMONE THERAPY PELLETT

*FarmaKeio Outsourcing is proud to announce the release of its latest innovation, the world's only patented hormone pellet with triamcinolone developed in an FDA-registered 503B outsourcing facility. The pellet is set to provide a new and revolutionary solution to hormone replacement therapy for men and women.*

### SOUTHLAKE, MAY 10, 2023 – FARMAKEIO 503B OUTSOURCING

FarmaKeio (FKO) Outsourcing, a leading pharmaceutical outsourcing facility in the United States, has been granted a patent to produce testosterone and triamcinolone subcutaneous hormone pellets. The patent includes 23 claims, issued by the United States Patent and Trademark Office (USPTO), recognizing the company's innovative approach to compounding hormone therapy and solidifies its position as a leader in the field of pharmaceutical development.

Unlike other hormone therapies, which may require frequent injections or daily pills, FarmaKeio Outsourcing's hormone pellets provide a sustained release of testosterone and triamcinolone, allowing patients to enjoy the benefits of these hormones for extended periods of time. These pellets are inserted subcutaneously and gradually release the hormone over several months, reducing the need for frequent dosing and allowing patients to focus on their daily lives.

"We are thrilled to receive this patent for our subcutaneous hormone pellets," said FarmaKeio Outsourcing's CEO, Dan DeNeui. "Our team has worked tirelessly to develop this innovative approach to hormone therapy, and we are excited to be able to offer this option to patients in need."

In addition to providing a more convenient method of hormone therapy, FarmaKeio's pellets offer a unique formulation that is not available from any other FDA 503B registered outsourcing facility in the US. This proprietary formulation has been carefully designed and tested and it represents a significant breakthrough in the field of hormone therapy.

"We believe that our hormone pellets have the potential to revolutionize the way that hormone therapy is delivered," said DeNeui. "By offering a sustained release of testosterone and triamcinolone, we can provide patients with a more consistent and reliable treatment option that can improve their quality of life."

The issuance of this patent is a significant milestone for FarmaKeio Outsourcing, and it reflects the company's ongoing commitment to innovation and excellence in pharmaceutical

development. As the demand for hormone therapy continues to grow, FarmaKeio is well-positioned to meet the needs of patients and healthcare providers alike with its cutting-edge hormone pellets.

"We are confident that our hormone pellets will become the gold standard for hormone therapy, and we look forward to working with healthcare providers and patients to make this technology available to as many people as possible," said Chief Operating Officer Cody Boatman.

The hormone pellet with triamcinolone is a groundbreaking new product that is set to revolutionize the hormone replacement therapy industry. With its unique combination of hormones and anti-inflammatory properties, it provides patients with a more comfortable treatment option. The pellet is an exclusive feature of The EvexiPEL Method, created and founded by Dr. Terri DeNeui, DNP, APRN, ACNP-BC and is available exclusively through FarmaKeio Outsourcing, an FDA-registered 503B facility. With this new product, FarmaKeio Outsourcing is once again proving its commitment to providing innovative solutions to hormone replacement therapy.

### ABOUT FARMAKEIO 503B OUTSOURCING

*FarmaKeio Outsourcing is a leading FDA-registered 503B pharmaceutical outsourcing facility that specializes in providing specific custom compounded medications to healthcare providers and facilities across the United States. FarmaKeio Outsourcing is committed to providing innovative, patient-centered solutions that meet the unique needs of their clients.*

*FarmaKeio Outsourcing offers an unwavering commitment to quality, safety, and compliance, operating a state-of-the-art facility that is cGMP compliant and undergoes rigorous testing and quality assurance procedures to ensure the highest level of quality and safety.*

*FarmaKeio Outsourcing provides exceptional customer service and support, ensuring that their clients have access to the resources and expertise necessary to make informed decisions about patient care. FarmaKeio Outsourcing is a trusted partner for healthcare providers looking to offer the most innovative and advanced care solutions to their patients.*